@article {Maruotti2021.11.17.21266455, author = {Antonello Maruotti and Giovanna Jona-Lasinio and Fabio Divino and Gianfranco Lovison and Massimo Ciccozzi and Alessio Farcomeni}, title = {Estimating COVID-19-induced Excess Mortality in Lombardy}, elocation-id = {2021.11.17.21266455}, year = {2021}, doi = {10.1101/2021.11.17.21266455}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {We compare the expected all-cause mortality with the observed one for different age classes during the pandemic in Lombardy, which was the epicenter of the epidemic in Italy and still is the region most affected by the pandemic. A generalized linear mixed model is introduced to model weekly mortality from 2011 to 2019, taking into account seasonal patterns and year-specific trends. Based on the 2019 year-specific conditional best linear unbiased predictions, a significant excess of mortality is estimated in 2020, leading to approximately 35000 more deaths than expected, mainly arising during the first wave. In 2021, instead, the excess mortality is not significantly different from zero, for the 85+ and 15-64 age classes, and significant reductions with respect to the 2020 estimated excess mortality are estimated for other age classes.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe research has been partially supported by the Ministero dell{\textquoteright}Istruzione, dell{\textquoteright}Universita{\textquoteright} e della Ricerca, project number FISR2020IP\_00156 "Modelli statistici inferenziali per governare l{\textquoteright}epidemia" (SMIGE).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors}, URL = {https://www.medrxiv.org/content/early/2021/11/17/2021.11.17.21266455}, eprint = {https://www.medrxiv.org/content/early/2021/11/17/2021.11.17.21266455.full.pdf}, journal = {medRxiv} }